IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies
Zhang, Y-y; Liu, D-h; Liu, K-y; Xu, L-p; Chen, H.; Han, W.; Wang, Y.; Huang, X-j
关键词Haploidentical Hematopoietic Sct Hematological Malignancy
刊名BONE MARROW TRANSPLANTATION
2014-04-01
DOI10.1038/bmt.2013.223
49期:4页:496-501
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]BONE-MARROW-TRANSPLANTATION ; ACUTE-LEUKEMIA ; MISMATCHED/HAPLOIDENTICAL BLOOD ; CLINICAL-OUTCOMES ; HIGH-RISK ; RELAPSE ; GRAFT ; ALLOREACTIVITY ; HAPLOTYPE ; LYMPHOMA
英文摘要

HLA-haploidentical hematopoietic SCT (HSCT) provides an opportunity for almost all patients who lack HLA-matched sibling donors. The donor availability can be increased by including the collateral related donors (CRDs). We compared clinical outcomes of patients with hematological malignancies, who underwent haploidentical HSCT from CRD (n=30) and immediate related donors (IRDs; n=120). In CRDs, 29 (96.7%) patients achieved sustained engraftment. In CRDs and IRDs, the median times of myeloid recovery were 13 (range 10-20 days) and 14 days (range 12-23 days), and the median times of platelet recovery were 18 (range 7-270) and 15 days (range 7-132 days; P=0.027). The incidences of II-IV acute GVHD were 27.6% versus 39.4% (P=0.058). The 2-year cumulative incidences of chronic GVHD (cGVHD) were 63.3% versus 57.8% (P=0.365). The 2-year incidence of extensive cGVHD of CRDs was significantly higher than that of IRDs (36.7% versus 20.2%, P=0.03). The 2-year incidences of relapse, 3-year probability of OS and leukemia-free survival for the two groups were 26.7% versus 14.8% (P=0.17), 56.7% versus 70.4% (P=0.224) and 50.0% versus 65.4% (P=0.103), respectively. This study shows that haploidentical HSCT from CRDs can provide a safe and effective treatment for patients with hematological malignancies. CRDs could be an alternative when there was no suitable IRDs.

语种英语
WOS记录号WOS:000334500900005
项目编号30971292 ; 7122193
资助机构National Clinical Key Specialties of China ; National Natural Science Foundation of China ; Beijing Natural Science Foundation
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57324
专题北京大学第二临床医学院_血液科
医学人文研究院/公共教学部_哲学与社会科学系
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Y-y,Liu, D-h,Liu, K-y,et al. HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies[J]. BONE MARROW TRANSPLANTATION,2014,49(4):496-501.
APA Zhang, Y-y.,Liu, D-h.,Liu, K-y.,Xu, L-p.,Chen, H..,...&Huang, X-j.(2014).HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies.BONE MARROW TRANSPLANTATION,49(4),496-501.
MLA Zhang, Y-y,et al."HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies".BONE MARROW TRANSPLANTATION 49.4(2014):496-501.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, Y-y]的文章
[Liu, D-h]的文章
[Liu, K-y]的文章
百度学术
百度学术中相似的文章
[Zhang, Y-y]的文章
[Liu, D-h]的文章
[Liu, K-y]的文章
必应学术
必应学术中相似的文章
[Zhang, Y-y]的文章
[Liu, D-h]的文章
[Liu, K-y]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。